United States

Antisense Therapeutics Ltd (ANP.AX)

ANP.AX on Australia Stock Exchange

17 Sep 2017
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Chart for


Antisense Therapeutics Limited (ANP) is an Australia-based pharmaceutical drug discovery and development company. The Company is engaged in the research and development of antisense pharmaceuticals. The Company's product candidate, ATL1103, is an antisense drug designed to block growth hormone receptor (GHr) expression thereby... (more)
No analyst recommendations are available for .


Beta: 1.75
Market Cap(Mil.): $6.71
Shares Outstanding(Mil.): 176.58
Dividend: --
Yield (%): --


  Industry Sector
P/E (TTM): -- 80.15 16.18
EPS (TTM): -- -- --
ROI: -- 3.01 14.60
ROE: -- 4.76 13.87

BRIEF-Antisense Therapeutics FY loss $2.8 mln

* FY net loss for period attributable $2.8 million Source text for Eikon: Further company coverage:

Aug 29 2017

BRIEF-Antisense Therapeutics updates on positive effects of a phase II study

* Phase II study has shown atl1102 significantly reduces number of active MS lesions that convert to "black holes" Source text for Eikon: Further company coverage:

Jun 15 2017

Earnings vs. Estimates

No consensus analysis data available.